Latest news with #NarayanaHrudayalaya
Business Upturn
29-05-2025
- Business
- Business Upturn
HSBC maintains reduce on Narayana Hrudayalaya, sees long gestation for India expansion
By News Desk Published on May 29, 2025, 07:56 IST HSBC has maintained a Reduce rating on Narayana Hrudayalaya with a target price of ₹1,220, even as the company posted an operational beat in Q4FY25, mainly driven by stronger-than-expected performance from its new Cayman Islands unit. The brokerage highlighted that while the Q4 numbers exceeded their expectations, the key driver was the Cayman facility, which ramped up ahead of schedule. However, HSBC remained cautious on the medium-term growth outlook, pointing out that the benefits from Narayana's ongoing bed expansion in India are still 3–4 years away. The firm believes that while the current momentum is encouraging, valuations already factor in much of the near-term optimism, and the long gestation period for Indian operations tempers their overall outlook. Disclaimer: The views and recommendations expressed above are those of the respective brokerage firm. Business Upturn does not endorse or offer any investment advice. News desk at
Yahoo
28-05-2025
- Business
- Yahoo
Narayana Hrudayalaya Ltd (BOM:539551) Q4 2025 Earnings Call Highlights: Strong Cayman Growth ...
Release Date: May 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Narayana Hrudayalaya Ltd (BOM:539551) has seen strong growth in its Cayman business, with new departments like urgent care and women's health contributing positively. The company has achieved a 45% margin in its Cayman operations, indicating strong financial performance. Narayana Hrudayalaya Ltd (BOM:539551) is focusing on organic growth through improved throughput and higher order procedures, which has sustained growth without adding new capacity. The company has a strong technology platform that enhances operational efficiency, allowing it to perform tasks with fewer resources. Narayana Hrudayalaya Ltd (BOM:539551) has a low debt-to-equity ratio, providing significant headroom for future borrowing if needed. The Indian business faces challenges with clinic and insurance losses, which are expected to grow as the company expands its clinic portfolio. There is a temporary increase in working capital days due to delayed payments from government payers, impacting cash flow. The company is experiencing a decline in international patient revenue, particularly from Bangladesh, which may continue to decrease. Narayana Hrudayalaya Ltd (BOM:539551) has not added significant new bed capacity in recent years, which may limit growth potential until new facilities are operational. The company faces challenges in retaining high-quality staff due to increasing competition in the healthcare sector. Warning! GuruFocus has detected 5 Warning Signs with KUASF. Q: Can you provide some color on the Cayman business growth and whether $45 million will be the new base for revenue? A: The hospital has been well-received, with new departments like urgent care and women's health contributing to growth. While there may be fluctuations, $45 million is a good base assumption for sustainable revenue. (Unidentified_3) Q: With Cayman margins at 45%, is there potential for further improvement, or will the focus shift to revenue growth? A: Beyond this point, focusing on improving margins at the expense of revenue growth doesn't make sense. The goal is now revenue growth, as crossing this margin level would be challenging and not sensible long-term. (Unidentified_3) Q: Regarding the Indian business, are the clinic and insurance losses at their peak, or could they extend further? A: The losses will grow due to expansion plans for clinics, but over 3-4 years, we aim to stay within a set investment horizon. The current cash burn is due to initial costs in new clinics and cities. (Unidentified_4) Q: What is the strategy for growth before the greenfield expansion kicks in? A: We will sustain growth through throughput initiatives, as seen in past years without adding capacity. We aspire to maintain the growth momentum without providing forward guidance. (Unidentified_4) Q: Can you elaborate on the insurance business and its reception among patients? A: Customers have responded positively, with about 4,000 lives covered. We focus on high-quality underwriting and risk management, providing an exceptional claims experience. Our strategy is to build distribution and expand to more markets. (Unidentified_6) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Business Standard
26-05-2025
- Business
- Business Standard
Narayana Hrudayalaya surges after Q4 PAT rises 3% YoY to Rs 197 cr
Narayana Hrudayalaya rallied 8.44% to Rs 1,870 after the company reported a 3.41% rise in consolidated net profit to Rs 197.21 crore on an 18.39% increase in revenue from operations to Rs 1,475.44 crore in Q4 FY25 over Q4 FY24. Profit before tax stood at Rs 253.02 crore during the quarter, registering a growth of 13.86% from Rs 222.22 crore reported in Q4 FY24. India's revenue stood at Rs 1,108.8 crore, up 10.66% year-on-year (YoY), while revenue from the Cayman Islands was Rs 379.7 crore, up 50.2% YoY. Consolidated EBITDA grew by 22.17% to Rs 384.6 crore in the March 2025 quarter from Rs 314.8 crore in Q4 FY24. EBITDA margin improved to 26.1% in Q4 FY25 as against 25.3% in Q4 FY24. On the margins front, the company's operating margin reduced to 24.25% in Q4 FY25, compared with 23.02% recorded in Q4 FY24. Net profit margin declined to 13.30% in Q4 FY25 from 14.91% registered in Q4 FY24. As of March 31, 2025, the companys total borrowings, net of cash, bank balances, and current investments, stood at Rs 533 crore. The net debt-to-equity ratio was at 0.15, with foreign currency-denominated debt amounting to $86.8 million. On a full-year basis, the company's net profit rose 0.11% to Rs 790.16 crore on a 12.12% rise in revenue to Rs 5,482.98 crore in FY25 over FY24. Dr. Emmanuel Rupert, managing director and group CEO, Narayana Hrudayalaya, said, The current financial year demonstrated strong performance across our units, both domestic and international; we are pleased to report the highest-ever revenues and profitability margins on both a quarterly and an annual basis at the consolidated level. The performance improvement in India units has been driven by domestic volume pickup, increased realizations, and optimization in payor categories. While our flagships continue to contribute significantly, our Southern Peripheral and North units have shown significant growth this year, and we hope to build on the momentum going forward. The new hospital in Camana Bay is fully functional and is contributing meaningfully to the overall Cayman business. We are excited about the traction in the new hospital and are confident that the region will deliver strong growth going forward. The integrated care business is picking up well, with our new clinics garnering sizeable footfalls. We will continue to invest in this business and are optimistic that it will be a significant driver of growth for the overall NH ecosystem. We thank the investor community for their faith in us and remain confident of delivering on expectations for the upcoming year. Meanwhile, the board has recommended a final dividend of Rs 4.50 per equity share for the financial year ended March 31, 2025. The record date for determining eligible shareholders has been set as Friday, 1 August 2025. Additionally, the board approved a proposal to seek shareholder approval via special resolution to raise up to Rs 1,500 crore in a financial year through the issuance of debt securities, including non-convertible debentures (NCDs), in one or more tranches on a private placement basis. The securities may be denominated in Indian rupees or foreign currency. Narayana Hrudayalaya is one of the leading healthcare service providers in India, operating a chain of multispecialty, tertiary, and primary healthcare facilities. The company has a network of 18 hospitals and 2 heart centers across India, along with an overseas presence in the Cayman Islands, with over 5,550 operational beds and a capacity of over 5,900 beds.
Business Standard
24-05-2025
- Business
- Business Standard
Narayana Hrudayalaya Q4 PAT grows 3% YoY to Rs 197 cr
Narayana Hrudayalaya reported a 3.41% rise in consolidated net profit to Rs 197.21 crore on an 18.39% increase in revenue from operations to Rs 1,475.44 crore in Q4 FY25 over Q4 FY24. Profit before tax stood at Rs 253.02 crore during the quarter, registering a growth of 13.86% from Rs 222.22 crore reported in Q4 FY24. India's revenue stood at Rs 1,108.8 crore, up 10.66% year-on-year (YoY), while revenue from the Cayman Islands was Rs 379.7 crore, up 50.2% YoY. Consolidated EBITDA grew by 22.17% to Rs 384.6 crore in the March 2025 quarter from Rs 314.8 crore in Q4 FY24. EBITDA margin improved to 26.1% in Q4 FY25 as against 25.3% in Q4 FY24. On the margins front, the company's operating margin reduced to 24.25% in Q4 FY25, compared with 23.02% recorded in Q4 FY24. Net profit margin declined to 13.30% in Q4 FY25 from 14.91% registered in Q4 FY24. As of March 31, 2025, the companys total borrowings, net of cash, bank balances, and current investments, stood at Rs 533 crore. The net debt-to-equity ratio was at 0.15, with foreign currency-denominated debt amounting to $86.8 million. On a full-year basis, the company's net profit rose 0.11% to Rs 790.16 crore on a 12.12% rise in revenue to Rs 5,482.98 crore in FY25 over FY24. Dr. Emmanuel Rupert, managing director and group CEO, Narayana Hrudayalaya, said, The current financial year demonstrated strong performance across our units, both domestic and international; we are pleased to report the highest-ever revenues and profitability margins on both a quarterly and an annual basis at the consolidated level. The performance improvement in India units has been driven by domestic volume pickup, increased realizations, and optimization in payor categories. While our flagships continue to contribute significantly, our Southern Peripheral and North units have shown significant growth this year, and we hope to build on the momentum going forward. The new hospital in Camana Bay is fully functional and is contributing meaningfully to the overall Cayman business. We are excited about the traction in the new hospital and are confident that the region will deliver strong growth going forward. The integrated care business is picking up well, with our new clinics garnering sizeable footfalls. We will continue to invest in this business and are optimistic that it will be a significant driver of growth for the overall NH ecosystem. We thank the investor community for their faith in us and remain confident of delivering on expectations for the upcoming year. Meanwhile, the board has recommended a final dividend of Rs 4.50 per equity share for the financial year ended March 31, 2025. The record date for determining eligible shareholders has been set as Friday, 1 August 2025. Additionally, the board approved a proposal to seek shareholder approval via special resolution to raise up to Rs 1,500 crore in a financial year through the issuance of debt securities, including non-convertible debentures (NCDs), in one or more tranches on a private placement basis. The securities may be denominated in Indian rupees or foreign currency. Narayana Hrudayalaya is one of the leading healthcare service providers in India, operating a chain of multispecialty, tertiary, and primary healthcare facilities. The company has a network of 18 hospitals and 2 heart centers across India, along with an overseas presence in the Cayman Islands, with over 5,550 operational beds and a capacity of over 5,900 beds. Shares of Narayana Hrudayalaya rose 0.01% to end at Rs 1,724.40 on Friday, 23 May 2025.
Business Standard
24-05-2025
- Business
- Business Standard
Narayana Hrudayalaya consolidated net profit rises 3.41% in the March 2025 quarter
Sales rise 18.39% to Rs 1475.44 crore Net profit of Narayana Hrudayalaya rose 3.41% to Rs 197.21 crore in the quarter ended March 2025 as against Rs 190.71 crore during the previous quarter ended March 2024. Sales rose 18.39% to Rs 1475.44 crore in the quarter ended March 2025 as against Rs 1246.25 crore during the previous quarter ended March 2024. For the full year,net profit rose 0.11% to Rs 790.16 crore in the year ended March 2025 as against Rs 789.26 crore during the previous year ended March 2024. Sales rose 12.12% to Rs 5482.98 crore in the year ended March 2025 as against Rs 4890.21 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 1475.441246.25 18 5482.984890.21 12 OPM % 24.2523.35 - 23.2823.47 - PBDT 343.88286.74 20 1222.011125.47 9 PBT 261.38222.22 18 943.90883.99 7 NP 197.21190.71 3 790.16789.26 0
